Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Medications › proteasome inhibitors

proteasome inhibitors

2 published articles · Updated continuously

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
IL-37 and IL-38 act as endogenous regulators of CAR-T-associated hyperinflammation in multiple myeloma
Oncology Sys. Review
IL-37 and IL-38 act as endogenous regulators of CAR-T-associated hyperinflammation in multiple myeloma New Proteins May Help Control Inflammation in Multiple Myeloma Treatment
This mini-review explores the roles of IL-37 and IL-38 as potential immunoregulatory checkpoints in patients with relapsed/refractory multip…
Two specific proteins, IL-37 and IL-38, may help control dangerous inflammation during CAR-T cell therapy for multiple myeloma.
Frontiers Aug 23, 2026
Narrative review explores natural products targeting proteasome in multiple myeloma
Drug Pipeline Sys. Review
Narrative review explores natural products targeting proteasome in multiple myeloma Natural Products May Help Beat Cancer Drug Resistance
This narrative review summarizes literature up to 2025 on natural products that directly target the proteasome or enhance sensitivity to pro…
New natural compounds may help overcome resistance to powerful cancer drugs, offering hope for patients who stop responding to treatment.
Frontiers May 4, 2026